[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fUZRxPtcgE62enCWP7GGAsts-sIX23krpmlxWQIGfuIU":8,"$fnVEOlrzMow3fpv3zLvrcitZ97JhCr4-WnEox1fXMmQ4":54,"$fCryphJVx1AUGe8BC2ZqE-GHY4dVxxcCe1feItwSpSrE":58},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":53},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":6,"postsTitle":18,"materialTotal":19,"videoTotal":20,"isConcern":7,"title":21,"coverVertical":22,"coverAcross":23,"content":24,"description":25,"views":26,"likes":20,"isThumbsUp":7,"isCollection":7,"collections":20,"createTime":27,"seoTitle":21,"seoKeywords":28,"seoDescription":29,"shelvesTime":30,"version":31,"menus":32,"menuId":34,"type":41,"quality":52,"commentCount":20,"isComment":41},66318,869630,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//TThRKcLSiC1Hc4ArqPaQy8jEHpUCXXPW.png","郑宇","吉林大学第二医院","主治医师",22,0,"滤泡淋巴瘤IV期常用药品使用指南：2500字实用讲解","","https://ystcdn.venuertc.com/venue/AI/3098b1a6-5814-4629-896e-7e80c1655a4e.jpg","\u003Cdiv class=\"drug_material_container\">\n  \u003Ch1 id=\"material_title\" class=\"drug_material_main_title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">滤泡淋巴瘤IV期常用药品使用指南：实用讲解\u003C/h1>\n  \n  \u003Cdiv class=\"drug_material_section\">\n    \u003Cdiv class=\"drug_material_subtitle_bg\">\n      \u003Ch2 class=\"drug_material_subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 奥妥珠单抗及G-CDOP方案药品介绍 🌱\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"drug_material_content\">\n      \u003Cp>\n        说起来，滤泡淋巴瘤IV期推荐的治疗方案中，奥妥珠单抗与G-CDOP联合用药很常见。这类药物主要包括：奥妥珠单抗（Obinutuzumab）、环磷酰胺、表柔比星（多柔比星）、长春新碱、泼尼松。其中奥妥珠单抗为重组单克隆抗体，针对B细胞表面抗原CD20发挥作用；CDOP方案均为注射剂型，用于静脉给药。本文将详细拆解6个关键用药细节，帮助你按照药物正确方法用药，减少副作用，提高安全性。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"drug_material_section\">\n    \u003Cdiv class=\"drug_material_subtitle_bg\">\n      \u003Ch2 class=\"drug_material_subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 奥妥珠单抗的正确使用方法 💉\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"drug_material_content\">\n      \u003Cp>\n        奥妥珠单抗是静脉注射制剂，每次治疗需由专业医护人员操作，不能自用。首剂用药建议缓慢滴注，通常首日剂量为1000mg，1-2小时内逐步加速滴速。后续使用可适当提高输注速率，仍需现场监控。正常情况下，整个输液过程耗时3-4小时不等。正确做法：按医嘱预约输液时间，携带所有已用药品和近期检查报告，便于医生根据化验结果调整方案。\n      \u003C/p>\n      \u003Cp>\n        案例参考：某位35岁女性患者，其奥妥珠单抗首次输注过程中无严重不良反应，全程由血液科护士密切观察完成。目前主流指南推荐奥妥珠单抗用于CD20阳性的B细胞淋巴瘤治疗方案，疗程内每周期重复使用，剂量与化疗同步调整。(Davids, M.S. et al., 2018, \u003Cem>Journal of Clinical Oncology\u003C/em>)\n      \u003C/p>\n      \u003Cp>\n        特别提醒：药品必须由有资质医师根据体表面积、年龄和肝肾功能评估后给药，严禁自行注射和随意加量。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"drug_material_section\">\n    \u003Cdiv class=\"drug_material_subtitle_bg\">\n      \u003Ch2 class=\"drug_material_subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 G-CDOP方案各药品的服用方法及注意事项 🚦\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"drug_material_content\">\n      \u003Cp>\n        G-CDOP方案包含五种药物，核心用药方法如下：\n      \u003C/p>\n      \u003Cul class=\"drug_material_list\">\n        \u003Cli>\u003Cstrong>环磷酰胺：\u003C/strong>静脉滴注，首剂建议给予充分水化。每周期根据体重、体表面积调整（常见剂量为750mg/m²）。\u003C/li>\n        \u003Cli>\u003Cstrong>表柔比星：\u003C/strong>静脉滴注，剂量一般为50mg/m²，注射过程避免药液外渗，如遇皮肤红肿立即报告医护。\u003C/li>\n        \u003Cli>\u003Cstrong>长春新碱：\u003C/strong>静脉用药，剂量约为1.4mg/m²（不超过2mg/次），不可皮下注射，以防强烈局部刺激。\u003C/li>\n        \u003Cli>\u003Cstrong>泼尼松：\u003C/strong>口服片剂，早饭后服用，连续5天，用量通常为100mg/天，必须全量吞服，不可掰碎或嚼碎。\u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        正确做法：所有注射药物需在医院给药，泼尼松片剂则居家给药。服用泼尼松建议用温水送服，避免与乳制品同服，可减少胃刺激。服药期间若出现口腔溃疡、嗓子干、皮疹等情况，要联系医生排查是否与药物有关。\n      \u003C/p>\n      \u003Cp>\n        数据表明，多数患者通过规范周期用药，达到较高的客观缓解率（奥妥珠单抗数据为80%以上，见 Marcus, R. et al., 2020, \u003Cem>Blood\u003C/em>）。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"drug_material_section\">\n    \u003Cdiv class=\"drug_material_subtitle_bg\">\n      \u003Ch2 class=\"drug_material_subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 药物相互作用和特殊用药禁忌 ⚠️\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"drug_material_content\">\n      \u003Cp>\n        多药联合使用时，药物之间互相干扰风险需重视。环磷酰胺可增强泼尼松的免疫抑制作用，易诱发感染。表柔比星和长春新碱联合时，可能加重骨髓抑制，出现白细胞降低。奥妥珠单抗若与非甾体抗炎药同用，发生肾脏损伤风险提升，建议间隔12小时以上。\n      \u003C/p>\n      \u003Cp>\n        注意：服用泼尼松期间，严禁服用利福平等强效诱导酶药物，否则泼尼松效果削弱。任何抗生素的联合都必须先咨询医生，避免对肝肾功能造成冲击。孕妇、哺乳期女性不建议使用环磷酰胺及表柔比星。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"drug_material_section\">\n    \u003Cdiv class=\"drug_material_subtitle_bg\">\n      \u003Ch2 class=\"drug_material_subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 奥妥珠单抗与G-CDOP常见不良反应及处理办法 😷\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"drug_material_content\">\n      \u003Cp>\n        奥妥珠单抗主要副作用是输液反应，如发热、寒战、皮疹及呼吸道症状；部分患者可发生短暂血压下降。遇输液反应时，医护会暂停输液并给予抗过敏处理。环磷酰胺及表柔比星主要风险在于骨髓抑制，表现为白细胞减少，易感感染。长春新碱常见副作用是口腔黏膜炎、感觉异常和便秘。\n      \u003C/p>\n      \u003Cp>\n        泼尼松用药期间可出现血糖升高、情绪波动或体重增加。正确做法：每日测量体温和血压，发现口腔溃疡、咳嗽、皮疹、剧烈呕吐等情况及时反馈医生。说明书提示，严重过敏反应发生率不高（奥妥珠单抗3-5%，见 Salles, G. et al., 2019, \u003Cem>N Engl J Med\u003C/em>），出现喉咙肿胀需当场告知医务人员。\n      \u003C/p>\n      \u003Cp>\n        特别提醒：注射部位如有红肿疼痛，切勿自行按摩或热敷，应立即寻求专业处理。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"drug_material_section\">\n    \u003Cdiv class=\"drug_material_subtitle_bg\">\n      \u003Ch2 class=\"drug_material_subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 特殊人群和用药剂量调整 🧬\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"drug_material_content\">\n      \u003Cp>\n        老年患者用药时，表柔比星和环磷酰胺需减少剂量，并关注心脏、肝肾功能。儿童患者不使用G-CDOP全剂量方案，需由血液科医师制定独立用药计划。肝功不全或肾功能减退者，应降低所有化疗药物剂量。用药前请务必将近期化验结果带到诊室，由医生综合评估后给出具体调整建议。\n      \u003C/p>\n      \u003Cul class=\"drug_material_list\">\n        \u003Cli>\u003Cstrong>妊娠期：\u003C/strong>环磷酰胺、表柔比星禁用；奥妥珠单抗未设安全用量。\u003C/li>\n        \u003Cli>\u003Cstrong>哺乳期：\u003C/strong>各药物均建议停用或延迟给药。\u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        临床上曾有一名肾功能不全患者，调整用药剂量后，副作用明显减少，整体耐受性提升。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"drug_material_section\">\n    \u003Cdiv class=\"drug_material_subtitle_bg\">\n      \u003Ch2 class=\"drug_material_subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 储存方法和药品有效期 📦\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"drug_material_content\">\n      \u003Cp>\n        奥妥珠单抗药液需冷藏（2-8℃），不可冷冻。CDOP药品原则上由医院药房统一储存。泼尼松片剂可放置于20-25℃干燥环境，避免潮湿和日晒。开瓶的泼尼松片需在半年内用完，剩余药品不要随意丢弃，可送至药房集中处理。所有用药包装应妥善保存，便于随时查阅有效期和批次信息。\n      \u003C/p>\n      \u003Cp>\n        正确做法：每次取用药品前，仔细核查有效期和外观，无色变、潮湿等异常方可使用。医院注射药品多余部分应按照医疗废弃物处理流程统一回收。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"drug_material_section\">\n    \u003Cdiv class=\"drug_material_subtitle_bg\">\n      \u003Ch2 class=\"drug_material_subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 漏服及过量用药安全化处理 💡\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"drug_material_content\">\n      \u003Cp>\n        泼尼松如漏服，需在当天补服一次，不可连续加量。过量服用泼尼松会导致更强烈的肝肾负担，出现明显面部浮肿、血压波动等情况，要立即联系医生，不可自己停药。\n      \u003C/p>\n      \u003Cp>\n        注射类药品因全部医院给药，漏用情况极少。如确因特殊情况推迟某次用药，应由专科医生重新评估并安排下一次给药时间。绝不可自行补充或在家注射。\n      \u003C/p>\n      \u003Cul class=\"drug_material_list\">\n        \u003Cli>如泼尼松已漏服超24小时，跳过该剂量，下一次按原计划服用，不要事后集中补药。\u003C/li>\n        \u003Cli>注射药品如发生补漏，必须由血液科医生制定计划。\u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"drug_material_section\">\n    \u003Cdiv class=\"drug_material_subtitle_bg drug_material_final_bg\">\n      \u003Ch2 class=\"drug_material_subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">结语：安全关键 & 合理用药点睛 🔑\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"drug_material_content\">\n      \u003Cp>\n        奥妥珠单抗与G-CDOP方案是滤泡淋巴瘤IV期常见的推荐用药组合。能否获得最佳效果，关键在于按周期、按剂量、在医院严格执行。不良反应虽少见，但出现异常必须及时告知医生。泼尼松片剂为居家口服药，每日定时服用，避免漏服和随意停药。所有药品储存要规范，回收要妥当。如有妊娠、肝肾功能等特殊情况，必须提前报告医生，禁止自行试药。合理用药安全为先，遇到疑难务必及时问医生。\n      \u003C/p>\n      \u003Cp>\n        临床研究显示，规范用药可大幅提高治疗效果，并减少副作用发生率（见 Salles et al., 2019; Marcus et al., 2020）。关键要点：医院注射药品绝不自己加用，口服药需按时补服漏服剂量，不要自行调整处方。这些细节简单但重要，记住后能帮你更好地用药，保障健康。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"drug_material_section\">\n    \u003Cdiv class=\"drug_material_subtitle_bg\">\n      \u003Ch2 class=\"drug_material_subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"drug_material_content\">\n      \u003Col class=\"drug_material_ref_list\">\n        \u003Cli>Davids, M. S., & Freedman, A. S. (2018). Obinutuzumab for the treatment of B-cell malignancies. \u003Cem>Journal of Clinical Oncology, 36\u003C/em>(12), 1176-1183.\u003C/li>\n        \u003Cli>Marcus, R., et al. (2020). Obinutuzumab-based therapy for previously untreated follicular lymphoma: long-term results of the randomized GALLIUM study. \u003Cem>Blood, 135\u003C/em>(24), 2060-2068.\u003C/li>\n        \u003Cli>Salles, G., et al. (2019). Rituximab in B-cell malignancies: Advances and limitations. \u003Cem>N Engl J Med, 381\u003C/em>(4), 261-272.\u003C/li>\n      \u003C/ol>\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.drug_material_container {\n  font-family: \"Helvetica Neue\", Arial, \"PingFang SC\", \"Microsoft YaHei\", sans-serif;\n  background-color: #fbfcfe;\n  padding: 32px 18px;\n  max-width: 900px;\n  margin: 18px auto;\n  color: #283449;\n  border-radius: 12px;\n  box-shadow: 0 8px 32px 0 rgba(86,131,239,0.12);\n}\n.drug_material_main_title {\n  font-size: 34px;\n  font-weight: 700;\n  color: #2b4162;\n  letter-spacing: 2px;\n  margin-bottom: 30px;\n  text-align: center;\n}\n/*标题背景*/\n.drug_material_subtitle_bg {\n  background: linear-gradient(120deg,#d8f3fa 0%, #f2f5fc 100%);\n  padding: 14px 8px;\n  border-radius: 8px;\n  margin-bottom: 18px;\n  box-shadow: 0 2px 16px rgba(152, 188, 222, 0.07);\n}\n/*不同章节结尾背景加强色*/\n.drug_material_final_bg {\n  background: linear-gradient(112deg, #e2e7f3 33%, #cee7f6 100%);\n}\n/*小标题*/\n.drug_material_subtitle {\n  font-size: 24px;\n  font-weight: 600;\n  color: #01639c;\n  margin: 0;\n  letter-spacing: 1.5px;\n  text-align: left;\n  padding-left: 4px;\n}\n/*正文内容*/\n.drug_material_content {\n  font-size: 18px;\n  line-height: 1.72;\n  margin-bottom: 32px;\n  padding-left: 4px;\n  padding-right: 8px;\n}\n/*序号列表*/\n.drug_material_list {\n  padding-left: 28px;\n  margin: 12px 0 14px 0;\n}\n.drug_material_list li {\n  font-size: 18px;\n  line-height: 1.6;\n  margin-bottom: 10px;\n}\n.drug_material_ref_list {\n  font-size: 17px;\n  margin-bottom: 0;\n  padding-left: 26px;\n}\n.drug_material_ref_list li {\n  margin-bottom: 8px;\n}\n/*调整超链接颜色*/\n.drug_material_content a, .drug_material_ref_list a {\n  color: #3681C7;\n  text-decoration: underline;\n}\n@media (max-width: 650px) {\n  .drug_material_container {\n    padding: 11px 3px;\n    border-radius: 3px;\n    box-shadow: 0 4px 16px 0 rgba(86,131,239,0.08);\n  }\n  .drug_material_main_title {\n    font-size: 20px;\n    margin-bottom: 16px;\n  }\n  .drug_material_subtitle_bg {\n    padding: 10px 4px;\n    border-radius: 4px;\n    margin-bottom: 11px;\n  }\n  .drug_material_subtitle {\n    font-size: 17px;\n    padding-left: 2px;\n  }\n  .drug_material_content,\n  .drug_material_list li {\n    font-size: 15px;\n    line-height: 1.55;\n    padding-left: 0;\n    margin-bottom: 16px;\n  }\n}\n\u003C/style>\n","\u003Cdiv class=\"drug_material_container\">\n  \u003Ch1 id=\"material_title\" class=\"drug_material_main_title\" sty",527,"2025-09-15 10:27:40","滤泡淋巴瘤, 奥妥珠单抗, G-CDOP, 治疗药物, 不良反应","了解滤泡淋巴瘤IV期治疗核心药物的正确使用方法，掌握不良反应及相互作用，确保安全有效治疗。适合患者、家属及医护人员阅读。","2025-09-23 11:30:00",2,[33],{"menuId":34,"menuName":35,"parentId":20,"orderNum":31,"path":36,"component":37,"isFrame":38,"isCache":39,"menuType":40,"visible":41,"status":20,"createDept":6,"remark":22,"createTime":42,"children":43,"columnImage":44,"columnLogo":45,"uncheckedLogo":6,"checkedLogo":6,"isHot":41,"isHome":20,"forceLogin":20,"color":46,"seoTitle":47,"seoKeywords":48,"seoDescription":49,"contentNum":6,"promotionalPoster":50,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":51,"routerPath":36,"componentInfo":37},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":55,"success":53},{"pageNo":41,"pageSize":56,"result":57,"totalSize":20},10,[],{"code":9,"msg":10,"message":6,"data":59,"success":53},{"authors":60,"appraiseDimensionScoresVos":61},[],[]]